ERBB2 and breast cancer: In conclusion, our results indicate that in patients with stage II-III HER2-positive breast tumors that are classified as HER2-type or HER2-single-type upon molecular characterization, the addition of pertuzumab to neoadjuvant chemotherapy and trastuzumab may improve pathological complete response and may decrease the risk of death due to breast cancer.